Sunday 18 October 2026
Export GNLX’s income statement to Excel — free account
Genelux Corporation
GNLX Healthcare Biotechnology
Genelux Corporation’s revenue for fiscal 2025 (year ended December 2025) was $8,000.00, roughly unchanged from fiscal 2024. In the quarter to June 2026, EPS fell 5.00% and free cash flow fell 11.2%, each against the same quarter a year earlier.
2.42
0.06
−2.42%
Follow GNLX
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | — | 5.35 | 1.60 | 1.99 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | — | — | 40.98 | 15.10 | 8.54 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | 15 | 15 | 25 | 24 | 26 | ||||
| Revenue/emp, $m | — | — | — | — | — | 0.00 | 0.74 | 0.01 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | 11 | 0 | 0 | 0 | ||||
| Gross margin, % | — | — | — | 0.00 | 0.00 | 0.00 | 100.00 | 100.00 | 100.00 | 100.00 | |||||
| EBT | — | — | — | (12) | (14) | (16) | (4) | (28) | (30) | (32) | |||||
| EBT margin, % | — | — | — | 0.00 | 0.00 | 0.00 | (37.11) | (16,645.29) | (373,362.50) | (401,812.50) | |||||
| Net income | — | — | — | (12) | (14) | (16) | (5) | (28) | (30) | (32) | |||||
| Depreciation | — | — | — | 0 | 1 | 1 | 1 | 1 | (1) | 0 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | 0.00 | 0.00 | 0.00 | 1.21 | 0.01 | 0.00 | 0.00 | ||||
| Earnings | — | — | — | (0.49) | (0.58) | (1.81) | (0.57) | (1.16) | (0.95) | (0.86) | |||||
| Cash flow | — | — | — | (0.31) | (0.31) | (0.73) | (0.39) | (0.83) | (0.67) | (0.68) | |||||
| Capex | — | — | — | 0.00 | 0.00 | 0.00 | (0.01) | (0.04) | (0.01) | (0.03) | |||||
| Free cash flow | — | — | — | (0.31) | (0.31) | (0.73) | (0.40) | (0.87) | (0.69) | (0.71) | |||||
| Book value | — | — | — | (1.05) | (0.96) | (3.67) | (3.93) | 0.80 | 0.84 | 0.31 | |||||
| Shares, m | — | — | — | 24 | 24 | 9 | 9 | 24 | 31 | 37 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| P/S | — | — | — | — | — | — | 0.00 | 0.00 | 6.60 | 14.41 | |||||
| P/B | — | — | — | — | — | — | 0.00 | 18.63 | 2.83 | 14.04 | |||||
| EV/Sales | — | — | — | — | — | — | 0.00 | 0.00 | 4.61 | 13.87 | |||||
| EV/FCF | — | — | — | — | — | — | (17.73) | (16.34) | (2.40) | (5.92) | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | (7) | (7) | (7) | (4) | (20) | (21) | (25) | ||||
| Capex | — | — | — | (2) | 0 | — | 0 | (1) | 0 | (1) | |||||
| Free cash flow | — | — | — | (7) | (7) | (7) | (4) | (21) | (22) | (26) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | (14) | (3) | (17) | (30) | 18 | 25 | 9 | ||||
| Total debt | — | — | — | 18 | 26 | 18 | 9 | — | — | — | |||||
| Net debt | — | — | — | 18 | 15 | 13 | 8 | (23) | (31) | (15) | |||||
| Shareholders’ equity | — | — | — | (25) | (23) | (33) | (36) | 19 | 26 | 12 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | 0.00 | (157.82) | (147.99) | (76.25) | (169.32) | (95.41) | (119.62) | ||||
| ROIC | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| ROE | — | — | — | 0.00 | 57.43 | 58.69 | 15.11 | 346.52 | (130.58) | (170.00) | |||||
Negative figures in brackets.
Fiscal years to Dec 2025 · latest quarter Mar 2024
Charts ten years each
Genelux Corporation vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| NERV Minerva Neurosciences, Inc | $115.6M | — (loss-making) | — (loss-making) | — | n/m | −553.48% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| ARMP Armata Pharmaceuticals, Inc. | $114.9M | — (loss-making) | — (loss-making) | +15.72% (above 0%: growing) | n/m | −17.98% (below 0%: shrinking) | 100.00% | (410.84%) | Compare |
| ENGN enGene Therapeutics Inc | $114.6M | — (loss-making) | — | — | n/m | +28.07% (above 0%: growing) | — | 0.00% | Compare |
| SEER Seer, Inc. | $113.0M | — (loss-making) | — (loss-making) | −23.43% (below 0%: shrinking) | n/m | +36.73% (above 0%: growing) | 48.55% | (542.91%) | Compare |
| FHTX Foghorn Therapeutics Inc. | $112.2M | — (loss-making) | — (loss-making) | +112.68% (above 0%: growing) | n/m | +14.88% (above 0%: growing) | 100.00% | (54.78%) | Compare |
| GNLX Genelux Corporation | $112.2M | — (loss-making) | — (loss-making) | — | n/m | −11.18% (below 0%: shrinking) | 100.00% | 0.00% | |
| LENZ LENZ Therapeutics, Inc. | $112.2M | — (loss-making) | — (loss-making) | +9.72% (above 0%: growing) | n/m | −229.66% (below 0%: shrinking) | 94.90% | (622.89%) | Compare |
| TNXP Tonix Pharmaceuticals Holding Corp. | $110.1M | — (loss-making) | — (loss-making) | +577.88% (above 0%: growing) | n/m | −178.84% (below 0%: shrinking) | 94.81% | (314.05%) | Compare |
| VTVT vTv Therapeutics Inc. | $109.1M | — (loss-making) | — (loss-making) | +409,222.22% (above 0%: growing) | n/m | −124.59% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| Median of peers | $112.6M | — | — | +64.20% | — | −71.28% | 94.90% | (184.41%) |
Genelux Corporation (GNLX) key facts
- Genelux Corporation (GNLX) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- Genelux Corporation’s revenue for fiscal 2025 (year ended December 2025) was $8,000.00, roughly unchanged from fiscal 2024.
- As of October 16, 2026, GNLX traded at $2.42, a market capitalization of $112.2 million.
- Return on equity was −170.0% and debt-to-equity 0.00.
- Its Piotroski F-score is 3 out of 9 and its Altman Z-score is −13.06 (distress zone) for fiscal 2025.
Genelux Corporation (GNLX) Latest News
No news at this impact. Lower the threshold for more.